HC Wainwright Has Pessimistic Outlook of SRTS Q2 Earnings

Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) - Analysts at HC Wainwright decreased their Q2 2025 earnings per share estimates for Sensus Healthcare in a report issued on Monday, February 10th. HC Wainwright analyst Y. Chen now forecasts that the company will earn $0.07 per share for the quarter, down from their previous forecast of $0.10. HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for Sensus Healthcare's current full-year earnings is $0.71 per share. HC Wainwright also issued estimates for Sensus Healthcare's FY2025 earnings at $0.44 EPS.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%.

Several other equities analysts have also weighed in on SRTS. Maxim Group increased their target price on Sensus Healthcare from $12.00 to $14.00 and gave the company a "buy" rating in a research note on Friday, November 15th. Lake Street Capital began coverage on Sensus Healthcare in a research note on Friday, January 31st. They issued a "buy" rating and a $18.00 target price on the stock.

Sensus Healthcare Trading Up 0.2 %

Shares of SRTS traded up $0.01 during trading hours on Wednesday, hitting $5.51. 270,397 shares of the stock traded hands, compared to its average volume of 394,988. Sensus Healthcare has a 1-year low of $2.91 and a 1-year high of $9.33. The business has a fifty day moving average of $7.15 and a 200-day moving average of $6.87. The firm has a market capitalization of $90.30 million, a PE ratio of 13.78 and a beta of 1.24.

Institutional Investors Weigh In On Sensus Healthcare

Hedge funds have recently modified their holdings of the business. Geode Capital Management LLC raised its position in shares of Sensus Healthcare by 8.5% during the third quarter. Geode Capital Management LLC now owns 146,404 shares of the company's stock worth $849,000 after purchasing an additional 11,525 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Sensus Healthcare during the second quarter worth about $156,000. XTX Topco Ltd raised its position in shares of Sensus Healthcare by 76.0% during the third quarter. XTX Topco Ltd now owns 31,530 shares of the company's stock worth $183,000 after purchasing an additional 13,619 shares during the period. Truvestments Capital LLC acquired a new stake in shares of Sensus Healthcare during the third quarter worth about $32,000. Finally, Renaissance Technologies LLC raised its position in shares of Sensus Healthcare by 5.3% during the fourth quarter. Renaissance Technologies LLC now owns 430,934 shares of the company's stock worth $2,982,000 after purchasing an additional 21,600 shares during the period. Institutional investors and hedge funds own 25.30% of the company's stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.